Note 13 - Segment Information

3 Months Ended

Jul. 31, 2014

Note 13 - Segment Information:

Note 13 - Segment Information

NOTE 13 - SEGMENT INFORMATION

The following information is presented in accordance with ASC Topic 280, “Segment Reporting”, for the three months ended July 31, 2014 and 2013; we operated in three reportable business segments - (1) natural sweetener (stevioside), (2) traditional Chinese medicines and (3) corporate and other. Our reportable segments are strategic business units that offer different products and are managed separately based on the fundamental differences in their operations. Condensed financial information with respect to these reportable business segments for the three months ended July 31, 2014 and 2013 is as follows:

	Three Months Ended July 31,
	2014	2013
Revenues:
Chinese medicine – third party	$                   522,194	$             571,560
Chinese medicine – related party	0	0
Total Chinese medicine	522,194	$             571,560
Stevioside – third party	2,428,707	1,002,035
Stevioside – related party	885,608	1,143,311
Total Stevioside	3,314,315	2,145,346
Total segment and consolidated revenues	$                3,836,509	$          2,716,906
Interest income (expense):
Chinese medicine	$                           139	$                     144
Stevioside	(63,093)	(15,532)
Corporate and other	0	0
Total segment and consolidated interest expense	$                    (62,954)	$              (15,388)
Depreciation and amortization:
Chinese medicine	$                     20,608	$                          0
Stevioside	685,804	545,665
Corporate and other	0	0
Total segment and consolidated depreciation and amortization	$                   706,412	$             545,665
Income (loss) before income taxes:
Chinese medicine	$                     24,115	$                (8,858)
Stevioside	(459,138)	(623,506)
Corporate and other	(69,181)	46,990
Total consolidated loss before income taxes	$                  (504,204	$            (585,374

	July 31, 2014	April 30, 2014
Segment tangible assets:
Chinese medicine	$        637,914	$        605,918
Stevioside	14,148,459	14,332,440
Corporate and other	0	0
Total consolidated assets	$  14,786,373	$  14,938,358